According to our recent payer coverage analysis for non-small cell lung cancer ALK+ or ROS1+ treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Payer Coverage: A review of market access for non-small cell lung cancer ALK+ or ROS1+ treatments shows that under the pharmacy benefit, about 75% of the lives under commercial formularies are covered with utilization management restrictions.
Trends: Competition is growing, with six different drugs from four different manufacturers targeting these gene mutations in patients with NSCLC.